Cancel anytime
ABVC Biopharma Inc (ABVC)ABVC
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/06/2024: ABVC (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -56.96% | Upturn Advisory Performance 1 | Avg. Invested days: 18 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/06/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -56.96% | Avg. Invested days: 18 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/06/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.08M USD |
Price to earnings Ratio - | 1Y Target Price 2.02 |
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Volume (30-day avg) 241356 | Beta 0.81 |
52 Weeks Range 0.41 - 2.45 | Updated Date 11/5/2024 |
Company Size Small-Cap Stock | Market Capitalization 7.08M USD | Price to earnings Ratio - | 1Y Target Price 2.02 |
Dividends yield (FY) - | Basic EPS (TTM) -1.66 | Volume (30-day avg) 241356 | Beta 0.81 |
52 Weeks Range 0.41 - 2.45 | Updated Date 11/5/2024 |
Earnings Date
Report Date 2024-11-13 | When BeforeMarket |
Estimate - | Actual - |
Report Date 2024-11-13 | When BeforeMarket | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -833.72% |
Management Effectiveness
Return on Assets (TTM) -44.55% | Return on Equity (TTM) -320.36% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 9634511 | Price to Sales(TTM) 60.11 |
Enterprise Value to Revenue 76.32 | Enterprise Value to EBITDA -1.9 |
Shares Outstanding 12421800 | Shares Floating 9137468 |
Percent Insiders 22.93 | Percent Institutions 2.95 |
Trailing PE - | Forward PE - | Enterprise Value 9634511 | Price to Sales(TTM) 60.11 |
Enterprise Value to Revenue 76.32 | Enterprise Value to EBITDA -1.9 | Shares Outstanding 12421800 | Shares Floating 9137468 |
Percent Insiders 22.93 | Percent Institutions 2.95 |
Analyst Ratings
Rating 3 | Target Price 2.02 | Buy - |
Strong Buy - | Hold 1 | Sell - |
Strong Sell - |
Rating 3 | Target Price 2.02 | Buy - | Strong Buy - |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
ABVC Biopharma Inc. - A Comprehensive Overview
Disclaimer: I am an AI chatbot and this information is for educational purposes only. It should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.
Company Profile
Detailed history and background: ABVC Biopharma Inc. (ABVC) is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in oncology and fibrosis. Founded in 2017 and headquartered in Fremont, California, ABVC utilizes its proprietary 3D bioprinting technology platform to create three-dimensional human tissues for drug discovery and development.
Core business areas: ABVC's core business areas include:
- Oncology: Developing innovative cancer therapies targeting specific tumor types and resistant cancers.
- Fibrosis: Focusing on treatments for fibrotic diseases affecting organs like the liver, lungs, and kidneys.
- 3D Bioprinting: Utilizing its proprietary technology to create bioprinted human tissues for drug discovery and development.
Leadership team and corporate structure: ABVC's leadership team comprises experienced professionals in the pharmaceutical and biotech industry. The company operates a lean organizational structure with a focus on research and development.
Top Products and Market Share:
Top products and offerings: Currently, ABVC does not have any marketed products. However, its pipeline includes several promising drug candidates:
- ABVC-001: A small molecule inhibitor targeting tyrosine kinases for the treatment of glioblastoma multiforme (GBM).
- ABVC-002: A next-generation EGFR inhibitor for the treatment of non-small cell lung cancer (NSCLC).
- ABVC-003: A first-in-class small molecule inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).
Market share: As ABVC currently has no marketed products, it does not hold any market share in the global or US markets.
Product performance and market reception: All of ABVC's drug candidates are currently in preclinical or early clinical development stages. Therefore, it is too early to assess their market performance and reception.
Total Addressable Market:
The global oncology market is estimated to reach $260.8 billion by 2027, growing at a CAGR of 10.7%. The global fibrosis market is expected to reach $24.2 billion by 2028, with a CAGR of 9.3%. Thus, ABVC operates in large and growing addressable markets.
Financial Performance:
Revenue and net income: ABVC currently generates no revenue, as it is in the pre-revenue stage. Net income is also negative due to research and development expenses.
Profit margins and EPS: As ABVC has no revenue, it does not have profit margins or EPS.
Financial performance comparison: Year-over-year comparisons are not possible due to the short operational history.
Cash flow statements and balance sheet health: ABVC's cash flow is primarily from financing activities, as it is in the development stage. Its balance sheet is characterized by high cash reserves and minimal liabilities.
Dividends and Shareholder Returns:
Dividend history: ABVC does not currently pay dividends due to its focus on reinvesting capital for growth.
Shareholder returns: Shareholder returns are negative since ABVC's IPO in 2021.
Growth Trajectory:
Historical growth: ABVC has experienced rapid growth in recent years, driven by its promising pipeline and technology platform.
Future growth projections: Future growth projections are highly dependent on the success of its clinical trials and drug approvals.
Recent product launches and strategic initiatives: ABVC has recently initiated several clinical trials for its drug candidates. It has also entered into strategic partnerships with other companies to advance its research and development efforts.
Market Dynamics:
Industry trends: The oncology and fibrosis markets are characterized by innovation, with a focus on developing targeted therapies and personalized medicine.
Demand-supply scenarios: Demand for novel cancer and fibrosis treatments is high, but the supply of effective therapies remains limited.
Technological advancements: ABVC's 3D bioprinting technology platform has the potential to accelerate drug discovery and development.
Industry positioning and adaptability: ABVC is well-positioned with its innovative drug candidates and technology platform to adapt to changing market dynamics.
Competitors:
Key competitors:
- In the oncology space: Amgen (AMGN), Bristol Myers Squibb (BMY), Pfizer (PFE)
- In the fibrosis space: Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Genfit (GNFT)
Market share comparisons: ABVC has no market share as it has no marketed products.
Competitive advantages and disadvantages:
- Advantages: Innovative drug candidates, proprietary 3D bioprinting technology.
- Disadvantages: Pre-revenue stage, limited clinical data, intense competition.
Potential Challenges and Opportunities:
Key challenges:
- Successfully completing clinical trials and obtaining regulatory approvals.
- Achieving commercial success for its drug candidates.
- Maintaining a strong financial position.
Potential opportunities:
- Expanding its pipeline through internal research and development or acquisitions.
- Partnering with other companies to accelerate drug development and commercialization.
- Entering new markets with high unmet medical needs.
Recent Acquisitions:
ABVC has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification: ABVC has a strong pipeline of promising drug candidates and a unique technology platform. However, it is still in the early stages of development and faces significant challenges.
Sources and Disclaimers:
Sources:
- ABVC Biopharma Inc. website: https://abvcbio.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Market research reports: https://www.grandviewresearch.com/
Disclaimer: This information is for educational purposes only and should not be considered financial advice. Please consult a qualified financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ABVC Biopharma Inc
Exchange | NASDAQ | Headquaters | Fremont, CA, United States |
IPO Launch date | 2017-10-11 | CEO & Interim CFO | Dr. Uttam Yashwant Patil Ph.D. |
Sector | Healthcare | Website | https://www.abvcpharma.com |
Industry | Biotechnology | Full time employees | 16 |
Headquaters | Fremont, CA, United States | ||
CEO & Interim CFO | Dr. Uttam Yashwant Patil Ph.D. | ||
Website | https://www.abvcpharma.com | ||
Website | https://www.abvcpharma.com | ||
Full time employees | 16 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.